Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (695)	7/5/2002 12:01:02 PM
From: tuck	Read Replies (1) \| Respond to of 1005

Curon tanks on release of this terse, gloomy, and uncertain statement. Theory was that well accepted treatments resisted economic downturns, and besides, the economy (if not the market) is supposed to be in slow recovery mode per recent data. Which makes this PR seem a bit disingenuous on its face. The earnings CC should be very interesting, but I won't be around to listen to it. Nigel, you and the other archiving posters are going to have to pull my load for a month or so. Embarking Sunday on a long road trip, expect to be back in early August, right about when you Euros take your vacations. I'll be checking in from time to time, but will not be doing much posting, if any, nor any meaningful research. >>SUNNYVALE, Calif., July 3 /PRNewswire-FirstCall/ -- Curon Medical, Inc. (Nasdaq: CURN - News) a provider of innovative proprietary products for the treatment of gastrointestinal disorders, today announced preliminary financial results for the second quarter ended June 30, 2002. Curon expects to report net revenue for the quarter in the range of $845,000 to $875,000. Curon retracts prior financial guidance. Given the state of the U.S. economy and the lack of visibility with regard to future performance, Curon does not expect to provide financial guidance for the remainder of the year. Earnings Release and Conference Call on July 17, 2002. Curon Medical will host a conference call at 4:30 p.m. eastern time on Wednesday, July 17, 2002 to discuss second quarter results. The live call may be accessed by dialing (913) 981-5507 and through a web cast at the Curon Medical website investor-curonmedical.com. The replay will be available for 30 days via web cast or by calling (719) 457-0820 from 7:30 p.m. eastern time until midnight eastern time on Tuesday, July 23, 2002. The confirmation number to access the replay is 548980.<< snip I further note that GNVC has not only gotten back into the 2s, it's into the 1s again. With control of it programs returned, this is now a highly leveraged company, with the risk/reward metric looking better than it has in months. Any biofreaks want to comment on GNVC's clinical prospects? Probably not, since so few biofreaks believe in gene therapy. Cheers, Tuck